Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available.

This document is a letter to the editor published in the journal Leukemia & Lymphoma. The letter discusses the long-term survival of patients with acute myeloid leukemia (AML) who have mutations in the nucleophosmin 1 (NPM1mut) gene. The study analyzed 179 newly diagnosed NPM1mut AML patients who were treated with intensive chemotherapy and had extensive molecular data available. The results showed that the presence of certain mutations, such as FLT3ITD and DNMT3AR882, significantly impacted overall survival. The study also identified a small group of patients who lived more than 5 years after AML diagnosis, and they were found to be younger and have fewer FLT3ITD mutations. [Extracted from the article]